Healionics’?STARgraft?Receives?FDA Breakthrough Device Designation
关于我们
Healionics is addressing the critical need for safer, more reliable means of bloodstream access to perform dialysis in patients with kidney failure. Our STARgraft vascular graft (synthetic blood vessel) is designed to resist the problems of occlusion and infection suffered by current devices. We also have an exciting product pipeline based on our platform STAR? biomaterial, which has a unique ability to prevent two serious problems that affect all implantable devices: scarring and infection. The company is currently conducting human studies of STARgraft and has 36 patents issued or pending.
- 网站
-
https://www.healionics.com
Healionics Corporation的外部链接
- 所属行业
- 医疗设备
- 规模
- 2-10 人
- 总部
- Seattle，WA
- 类型
- 私人持股
- 创立
- 2007
地点
-
主要
获取路线
2121 N. 35th Street
Suite 200
US，WA，Seattle，98103
Healionics Corporation员工
动态
-
Healionics announces 12-month clinical results for STARgraft
Healionics announces 12-month clinical results for STARgraft
einpresswire.com
-
Clinical results for Healionics’ STARgraft featured at VASA conference
Clinical results for Healionics’ STARgraft featured at VASA conference
einpresswire.com
-
Healionics Awarded $1.25M NIH Grant to Support Commercialization of STARgraft Vascular Graft
Healionics Awarded $1.25M NIH Grant to Support Commercialization of STARgraft Vascular Graft
einpresswire.com
-
Thanks to Park City Angels for their interest and support!
Park City Angels is excited to announce that our members have made an investment in Healionics Corporation https://healionics.com/. Click on these photos to learn more! #venturecapital #growth #startups #investment #parkcity #parkcityutah #Healionics #innovation #angelinvesting
-
-
Healionics Closes $5.5 Million Series A-3 Financing Round
Healionics Closes $5.5 Million Series A-3 Financing Round
einnews.com
-
Thanks to Angel Star Ventures for your diligence and investment!
#AngelStarVentures?(https://lnkd.in/gisVCZZn) is expanding our portfolio and happy to announce our investment in?Healionics Corporation, developing #STARgraft vascular graft to substantially improve health, longevity, and quality of life for kidney failure patients, while reducing treatment cost. We are excited to work with?Mike Connolly ?and the team at HEALIONICS to bring this breakthrough platform technology to improve #healthcare.
Home
angelstarventures.com
-
Thanks to Keiretsu Forum London!
???We’re thrilled to kick off 2024 with our first investment of the year: Healionics Corporation! We are proud to support?Mike Connolly and the team in revolutionizing safe bloodstream access to perform dialysis in patients with kidney failure. This is a vital innovation for the millions of people impacted by kidney disease gloablly ???? Visit?https://healionics.com/?to find out more about Healionics?and reach out if you'd like to get funded: [email protected]. #KeiretsuBacked
-